United Kingdom Thyroid Disorder Market Insight
United Kingdom Thyroid Disorder Market is growing at an 7.7% CAGR, by rising thyroid disorder prevalence, advanced diagnostics
United Kingdom Thyroid Disorder Market Insights Forecasts to 2035
- The United Kingdom Thyroid Disorder Market Size Was Estimated at USD 444.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.7% from 2025 to 2035
- The United Kingdom Thyroid Disorder Market Size is Expected to Reach USD 933.4 Million by 2035
Notable Insights for United Kingdom Thyroid Disorder Market
- By disorder type, hypothyroidism dominated, accounting for approximately 65% share in 2024, driven by increasing diagnosis rates and long-term hormone replacement therapy demand.
- By treatment type, levothyroxine therapy dominated, holding approximately 75% share, owing to its widespread use as the standard treatment for hypothyroidism.
- Approximately 5% of the UK population is affected by thyroid disorders, with higher prevalence observed among women and elderly populations.
- Around 80% of diagnosed patients receive long-term medication management, while a smaller proportion require surgery, radioactive iodine therapy, or combination treatments.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Thyroid Disorder Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Thyroid Disorder Market
- AbbVie
- Pfizer
- GlaxoSmithKline
- Merck KGaA
- Viatris
- Sanofi
- IBSA Pharma
- Fresenius Kabi
- Others
Recent Developments:
- In May 2025, the MHRA approved teprotumumab (Tepezza) as the first licensed UK treatment for adults with moderate-to-severe thyroid eye disease, supporting advancements in thyroid disorder therapeutics nationwide.
- In January 2025, ThyroidPrint, a molecular diagnostic test, began trials across eight NHS Foundation Trusts to improve benign thyroid nodule detection and potentially reduce unnecessary thyroid surgeries in the UK.
Market Segmentation:
United Kingdom Thyroid Disorder Market, By Disorder Type
- Hypothyroidism
- Hyperthyroidism
- Thyroid Cancer
- Others
United Kingdom Thyroid Disorder Market, By Treatment Type
- Hormone Replacement Therapy
- Anti-thyroid Medications
- Radioactive Iodine Therapy
- Surgery
- Others
United Kingdom Thyroid Disorder Market, By Route of Administration
- Oral
- Injectable
United Kingdom Thyroid Disorder Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Endocrine Centers
United Kingdom Thyroid Disorder Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
Market Growth in the UK Thyroid Disorder Market is projected to be moderate owing to the increasing incidence of thyroid diseases, increased awareness regarding the importance of endocrinal health, and an increase in screening programs. It is believed that hormonal replacement medications like levothyroxine will continue to account for a dominant position in the market owing to the efficacy of these medicines and their popularity among medical practitioners.